Literature DB >> 7895462

Mortality in diabetic subjects: an eleven-year follow-up of a community-based population.

D P Walters1, W Gatling, A C Houston, M A Mullee, S A Julious, R D Hill.   

Abstract

In 1979, all the known diabetic subjects (849) were identified from a community (population 81851), of whom 717 (85%) were reviewed by a single observer. Using the NHS Central Register, follow-up was completed for 98% of subjects. After 11 years, 306 (42.7%) diabetic subjects had died, of whom 65 were insulin treated and 241 were non-insulin treated. Circulatory disease accounted for 168 (54.9%) deaths, of which 124 (73.8%) were due to ischaemic heart disease. The standardized mortality ratio (SMR) for all causes of death, based on data from England and Wales, was significantly raised for both insulin-treated and non-insulin-treated patients (1.75, 95% CI 1.35 to 2.24 and 1.32, 95% CI 1.15 to 1.50, respectively). SMRs for all cause mortality were significantly greater for diabetic subjects in the 45-64 (SMR, 1.97, 95% CI 1.34 to 2.80), 65-74 (SMR 1.59, 95% CI 1.27 to 1.97 and 75 years and over (SMR 1.26, 95% CI 1.08 to 1.45) age ranges. Using a proportional hazards model, after adjusting for age and gender, systolic blood pressure and vibration threshold were significant predictors of all cause mortality in insulin-treated subjects. For non-insulin-treated subjects, blood glucose, systolic blood pressure, glycated haemoglobin, retinopathy, proteinuria, coronary artery disease, and stroke were significant baseline predictors of mortality. No association was found for serum cholesterol, body mass index, diastolic pressure or cigarette smoking in either treatment group.

Entities:  

Mesh:

Year:  1994        PMID: 7895462     DOI: 10.1111/j.1464-5491.1994.tb00255.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  8 in total

1.  All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999.

Authors:  S S Soedamah-Muthu; J H Fuller; H E Mulnier; V S Raleigh; R A Lawrenson; H M Colhoun
Journal:  Diabetologia       Date:  2006-01-24       Impact factor: 10.122

2.  Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus.

Authors:  S V Koskinen; A R Reunanen; T P Martelin; T Valkonen
Journal:  Am J Public Health       Date:  1998-05       Impact factor: 9.308

3.  Patients' experiences of continuity in the care of type 2 diabetes: a focus group study in primary care.

Authors:  Mohammed H Alazri; Richard D Neal; Phil Heywood; Brenda Leese
Journal:  Br J Gen Pract       Date:  2006-07       Impact factor: 5.386

4.  The JEVIN trial: a population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990.

Authors:  R Schiel; U A Müller; H Sprott; A Schmelzer; B Mertes; W Hunger-Dathe; I S Ross
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

5.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Authors:  R C Turner; H Millns; H A Neil; I M Stratton; S E Manley; D R Matthews; R R Holman
Journal:  BMJ       Date:  1998-03-14

6.  Proliferative retinopathy and proteinuria predict mortality rate in type 1 diabetic patients from Fyn County, Denmark.

Authors:  J Grauslund; A Green; A K Sjølie
Journal:  Diabetologia       Date:  2008-02-23       Impact factor: 10.122

7.  Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in Finland.

Authors:  Noël C Barengo; Yvonne Teuschl; Vladislav Moltchanov; Tiina Laatikainen; Pekka Jousilahti; Jaakko Tuomilehto
Journal:  Tob Induc Dis       Date:  2017-02-02       Impact factor: 2.600

8.  Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K.

Authors:  Alexandra J Ward; Maribel Salas; J Jaime Caro; David Owens
Journal:  Cost Eff Resour Alloc       Date:  2004-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.